Connect Biopharma Limite... (CNTB)
1.05
-0.04 (-3.67%)
At close: Jan 14, 2025, 3:59 PM
1.06
0.94%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 1.03 |
| Market Cap | 58.02M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.39 |
| PE Ratio (ttm) | -2.69 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.1 |
| Volume | 8,734 |
| Avg. Volume (20D) | 28,834 |
| Open | 1.07 |
| Previous Close | 1.09 |
| Day's Range | 1.05 - 1.09 |
| 52-Week Range | 0.90 - 2.66 |
| Beta | undefined |
About CNTB
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosin...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 19, 2021
Employees 81
Stock Exchange NASDAQ
Ticker Symbol CNTB
Website https://www.connectbiopharm.com
Analyst Forecast
According to 1 analyst ratings, the average rating for CNTB stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 661.83% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
10 months ago ·
Source
+15.25%
Connect Biopharma Holdings shares are trading high...
Unlock content with
Pro Subscription
